C F Jehn1, B Becker2, B Flath3, H Nogai4, L Vuong4, P Schmid5, D Lüftner4. 1. University Hospital Charité Berlin, Department of Hematology, Oncology and Tumor Immunology, Germany. Electronic address: Christian.Jehn@charite.de. 2. Department of Immunology, Germany. 3. HOPA Hamburg, Germany. 4. University Hospital Charité Berlin, Department of Hematology, Oncology and Tumor Immunology, Germany. 5. Barts Cancer Institute, London, United Kingdom.
Abstract
BACKGROUND: Increased IL-6 and decreased brain-derived neurotrophic factor (BDNF) levels have been implicated in the pathophysiology of depression. The objective was to assess the influence of BDNF and IL-6 on cognitive function and depression in patients with cancer. METHODS: Serum BDNF and plasma IL-6 were measured in patients with metastatic cancer. Diagnosis of depression was established according to DSM-IV criteria. Cognitive function was assessed by the Verbal Learning and Memory Test (VLMT). RESULTS: A total of 59 patients were recruited in this study. Only IL-6 levels were significantly elevated in patients with clinical depression (35.7 vs. 6.9 pg/ml; p<0.001). There were no differences in hemoglobin levels (p=0.3) or BDNF levels (p=0.16). Patients with clinical depression showed significant impairment of short-term memory (STM) (24.4 vs. 37.5; p=0.01), but not of long-term memory (LTM) (3.9 vs. 2.8; p=0.3). STM was dependent on the level of BDNF and younger age (b=0.60; p=0.001; b= -0.63; p=0.003, respectively). IL-6 was not only strongly associated with depression, but was an independent predictor of BDNF level as well (b= -0.50; p=0.01). LTM was associated only with a good KPS (b=0.47; p=0.037). Hemoglobin levels and the prior number of chemotherapy lines were not predictive of memory performance. CONCLUSIONS: Low BDNF is associated with cognitive impairment, STM, in patients with cancer, however no influence on depression could be found. IL-6 is strongly associated with depression and an independent predictor of BDNF levels.
BACKGROUND: Increased IL-6 and decreased brain-derived neurotrophic factor (BDNF) levels have been implicated in the pathophysiology of depression. The objective was to assess the influence of BDNF and IL-6 on cognitive function and depression in patients with cancer. METHODS: Serum BDNF and plasma IL-6 were measured in patients with metastatic cancer. Diagnosis of depression was established according to DSM-IV criteria. Cognitive function was assessed by the Verbal Learning and Memory Test (VLMT). RESULTS: A total of 59 patients were recruited in this study. Only IL-6 levels were significantly elevated in patients with clinical depression (35.7 vs. 6.9 pg/ml; p<0.001). There were no differences in hemoglobin levels (p=0.3) or BDNF levels (p=0.16). Patients with clinical depression showed significant impairment of short-term memory (STM) (24.4 vs. 37.5; p=0.01), but not of long-term memory (LTM) (3.9 vs. 2.8; p=0.3). STM was dependent on the level of BDNF and younger age (b=0.60; p=0.001; b= -0.63; p=0.003, respectively). IL-6 was not only strongly associated with depression, but was an independent predictor of BDNF level as well (b= -0.50; p=0.01). LTM was associated only with a good KPS (b=0.47; p=0.037). Hemoglobin levels and the prior number of chemotherapy lines were not predictive of memory performance. CONCLUSIONS: Low BDNF is associated with cognitive impairment, STM, in patients with cancer, however no influence on depression could be found. IL-6 is strongly associated with depression and an independent predictor of BDNF levels.
Authors: Jan Engelmann; Stefanie Wagner; Daniel Wollschläger; Sabine Kaaden; Konrad F Schlicht; Nadine Dreimüller; Dieter F Braus; Marianne B Müller; Oliver Tüscher; Helge Frieling; André Tadić; Klaus Lieb Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-03-30 Impact factor: 5.270
Authors: Mohammad Malekan; Sasan Salehi Nezamabadi; Elham Samami; Mehdi Mohebalizadeh; Amene Saghazadeh; Nima Rezaei Journal: J Cancer Res Clin Oncol Date: 2022-09-29 Impact factor: 4.322
Authors: Daniel C McFarland; Meredith Doherty; Thomas M Atkinson; Robin O'Hanlon; William Breitbart; Christian J Nelson; Andrew H Miller Journal: Cancer Date: 2022-04-13 Impact factor: 6.921
Authors: Lin Yang; Ai Koyanagi; Lee Smith; Liang Hu; Graham A Colditz; Adetunji T Toriola; Guillermo Felipe López Sánchez; Davy Vancampfort; Mark Hamer; Brendon Stubbs; Thomas Waldhör Journal: PLoS One Date: 2018-06-04 Impact factor: 3.240